CLINUVEL PHARMACEUTICALS
Clinuvel Pharmaceuticals Limited is a biopharmaceutical company. The Company is focused on developing drugs for the treatment of a range of severe skin disorders. Its lead compound, SCENESSE (afamelanotide 16 milligrams), prevents phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The Company focuses at preventing the symptoms of skin diseases related to the exposure to harmful ultra violet (UV) radiation and at repigmentation of the ski... n due to a number of depigmentation disorders. SCENESSE has completed Phase II and III trials in the United States and Europe, and has been granted marketing authorization by the European Commission for adults with EPP. It has operations in Europe, the United States and Singapore. SCENESSE acts by increasing the levels of melanin in the skin and shields against UV radiation (UVR) and sunlight. SCENESSE is delivered via a subcutaneous dissolving implant.
CLINUVEL PHARMACEUTICALS
Industry:
Biotechnology Developer Platform Pharmaceutical
Founded:
2001-01-01
Address:
Melbourne, Victoria, Australia
Country:
Australia
Website Url:
http://www.clinuvel.com
Total Employee:
11+
Status:
Active
Contact:
61 3 9660 4900
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome Domain Not Resolving Wordpress Plugins
Current Employees Featured
Stock Details
Acquisitions List
Date | Company | Article | Price |
---|---|---|---|
2014-07-27 | Travere Therapeutics | Travere Therapeutics acquired by Clinuvel Pharmaceuticals | 95 M USD |
Official Site Inspections
http://www.clinuvel.com Semrush global rank: 2.39 M Semrush visits lastest month: 7.69 K
- Host name: 175.37.109.208.host.secureserver.net
- IP address: 208.109.37.175
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260